Top 5 Music VC (Venture Capital) Funds in Switzerland in November 2024

Last updated: Nov 2024 A list of 5 VC (Venture Capital) funds that invest in Music startups based in Switzerland. We rank investors based on the number of investments they made in Music companies from Switzerland. We update this investor list every month.

Top 5 Music VC (Venture Capital) Funds in Switzerland in November 2024

Investor	Music Switzerland investments
Zürcher Kantonal Bank	3
Verve Ventures	2
Serpentine Ventures	2
CV VC	1
Wilmaa	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Drone Harmony AG — Drone Harmony was founded in 2016 by a team of problem solvers with a passion for drones, software and automation. From their very early days, they have set out to tackle the mathematical and engineering challenges of enabling cost-effective deployment of drone technology in industries, where existing technologies were unable to deliver.DroneHarmony reinvents the way people fly drones commercially. Its 3D flight planning software turns anyone with a drone into an inspection professional. Sophisticated algorithms reduce complex industrial inspection tasks to automated and scalable workflows.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.

Serpentine Ventures (SERV) is the investment arm of the Swiss startup group. Serpentine refers to the meandering roads found across the Swiss Mountains. Unreachable mountain peaks become accessible by following the serpentine path.